Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 35-43 , May 2009

Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies

  • Leon A. Assael, DMD

      Affiliations

    • Professor and Chairman, Department of Oral and Maxillofacial Surgery, and Medical Director, Hospital Dentistry, Oregon Health and Science University, Portland, OR
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Assael: SDOMS, Oregon Health and Science University, 611 SW Campus Dr, Portland, OR 97239

References 

  1. FDA approves Actonel (risedronate) for osteoporosis. http://www.pslgroup.com/dg/1cd17e.htmAccessed March 5, 2009
  2. Roche our history. http://www.roche.com/home/company/com_hist/com_hist_2001.htmAccessed March 5, 2009
  3. Merck & Co, Inc. Regarding Fosamax (alendronate sodium) and rare cases of osteonecrosis of the jaw. http://www.merck.com/newsroom/press_releases/product/fosamax_statement.htmlAccessed March 5, 2009
  4. Lane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005;76:1113
  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  6. Schwabe U, Ziegler R. Mineralstoffpräparate und Osteoporosemittel. In:  Schwabe U,  Paffrath D editor. Arzneiverordnungsreport 2005. Heidelberg: Springer; 2005;p. 755–756
  7. Allen M, Burr D. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008;66:987
  8. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007;41:318
  9. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839
  10. Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA. Bone turnover and bone collagen maturation in osteoporosis: Effects of antiresorptive therapies. Osteoporos Int. 2008;19:339
  11. Grbic J, Landesberg L, Lin S, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc. 2008;139:32
  12. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415
  13. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: A retrospective study. Endocr Pract. 2007;13:232
  14. Falsenberg D, Hoffmeister B, Amling M, et al. Onkologie: Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arztebl. 2006;103:A-3078
  15. Abu-Id MH, Warnke PH, Gottschalk J, et al. “Bis-phossy jaws”—High and low risk factors for bisphosphonate induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2008;36:95
  16. Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753;erratum, Ann Intern Med 145:235, 2006
  17. Bilezikian JP. Osteonecrosis of the jaw —Do bisphosphonates pose a risk?. N Engl J Med. 2006;355:22
  18. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy?. Ann Oncol. 2006;17:1197
  19. Diel IJ, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and nonaminobisphosphonates?. Crit Rev Oncol Hematol. 2007;64:198
  20. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548
  21. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  22. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479
  23. Hamada S. Osteonecrosis of jaw associated with oral application of bisphosphonates. J Oral Maxillofac Surg. 2007;65:43
  24. Wessel J, Dodson T, Zafras A. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg. 2008;66:625
  25. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: The rheumatologist's role. Arthritis Res Ther. 2006;8:219
  26. Cartsos V, Zhu S, Zavras A. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc. 2008;139:23
  27. Montebugnoli L, Felicetti L, Gissi DB, et al. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:473
  28. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415
  29. Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007;18:1363
  30. Hoff AO, Toth BB, Altundag K, et al. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Min Res. 2008;6:826
  31. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:186
  32. Campisi G, Di Fede O, Musciotto A, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Run dental management designs and issues in diagnosis. Ann Oncol. 2007;18(suppl 6):168
  33. Chacon G, Stine E, Larsen P, et al. Effect of alendronate on endosseous implant integration: An in vivo study in rabbits. J Oral Maxillofac Surg. 2006;64:1005
  34. Bell BM, Bell RE. Oral bisphosphonates and dental implants: A retrospective study. J Oral Maxillofac Surg. 2008;66:1022
  35. Grant BT, Amenedo C, Freeman K, et al. Outcomes of placing dental implants in patients taking oral bisphosphonates: A review of 115 cases. J Oral Maxillofac Surg. 2008;66:223
  36. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol. 2007;78:584
  37. Arce K, Assael L, Weissman JL, et al. Imaging findings in bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(suppl 1):75
  38. Catalano L, Del Vecchio S, Petruzziello F, et al. Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Ann Hematol. 2007;86:415
  39. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A randomized trial. JAMA. 2006;296:2927
  40. Brown JE, Ellis SP, Lester JE, et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res. 2007;13:5406
  41. Rosen HN, Moses AC, Garber J. Serum CTX (A new marker of bone resorption that shows treatment effects more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy). Calcif Tissue Int. 2000;66:100
  42. Marx R, Cillo J, Ulloa J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  43. Assael L. Serum CTX to prevent osteonecrosis/orthodontic extraction of third molars: Paths toward minimizing surgical risk?. J Oral Maxillofac Surg. 2007;65:2395
  44. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809
  45. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. HORIZON Recurrent Fracture Trial (Zoledronic acid and clinical fractures and mortality after hip fracture). N Engl J Med. 2007;357:1799
  46. Bone HG, Hosking D, Devogeloer JD, et al. Alendronate Phase III Osteoporosis Treatment Study Group Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189

 Dr Assael is a paid consultant for Novartis and has received honoraria from Novartis and Merck.

PII: S0278-2391(09)00070-6

doi: 10.1016/j.joms.2009.01.003

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 35-43 , May 2009

Article Tools